Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Broly

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
Pharmacogenetics|June 1, 1993
Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 geneF Broly, U A Meyer
Annales Pharmaceutiques Francaises|November 23, 2006
[Therapeutic failure: importance of genes?]M Lhermitte, D Allorge, F Broly
Journal of Chromatography|October 14, 1988
High-performance liquid chromatographic assay for mexiletine hydroxylation in microsomes of human liverF Broly, C Libersa, M Lhermitte
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1990
Mexiletine metabolism in vitro by human liverF Broly, C Libersa, M Lhermitte
Clinical Neuropharmacology|October 1, 1994
Genetic polymorphism of cytochrome P450 2D6 in idiopathic Parkinson disease and diffuse Lewy body diseaseR Bordet, F Broly, A Destee, et al.
British Journal of Clinical Pharmacology|October 1, 1991
The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidationF Broly, N Vandamme, C Libersa, et al.
Advances in Neurology|January 1, 1996
Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's diseaseR Bordet, F Broly, A Destée, et al.
Revue Neurologique|April 13, 2011
[L-carnitine treatment and fish odor syndrome: an unwaited adverse effect]F Rocher, C Caruba, F Broly, et al.
Biochemical Pharmacology|March 15, 1990
Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomesF Broly, C Libersa, M Lhermitte, et al.
Pharmacopsychiatry|April 30, 1998
Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotypingP Baumann, F Broly, M Kosel, et al.
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Pharmacogenetics|June 1, 1993
Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 geneF Broly, U A Meyer
Annales Pharmaceutiques Francaises|November 23, 2006
[Therapeutic failure: importance of genes?]M Lhermitte, D Allorge, F Broly
Journal of Chromatography|October 14, 1988
High-performance liquid chromatographic assay for mexiletine hydroxylation in microsomes of human liverF Broly, C Libersa, M Lhermitte
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1990
Mexiletine metabolism in vitro by human liverF Broly, C Libersa, M Lhermitte
Clinical Neuropharmacology|October 1, 1994
Genetic polymorphism of cytochrome P450 2D6 in idiopathic Parkinson disease and diffuse Lewy body diseaseR Bordet, F Broly, A Destee, et al.
British Journal of Clinical Pharmacology|October 1, 1991
The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidationF Broly, N Vandamme, C Libersa, et al.
Advances in Neurology|January 1, 1996
Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's diseaseR Bordet, F Broly, A Destée, et al.
Revue Neurologique|April 13, 2011
[L-carnitine treatment and fish odor syndrome: an unwaited adverse effect]F Rocher, C Caruba, F Broly, et al.
Biochemical Pharmacology|March 15, 1990
Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomesF Broly, C Libersa, M Lhermitte, et al.
Pharmacopsychiatry|April 30, 1998
Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotypingP Baumann, F Broly, M Kosel, et al.
Pageof 7